Cargando…
Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes
In diabetes mellitus (DM) treatment, Continuous Glucose Monitoring (CGM) linked with insulin delivery becomes the main strategy to improve therapeutic outcomes and quality of patients’ lives. However, Blood Glucose (BG) regulation with CGM is still hampered by limitations of algorithms and glucose s...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072637/ https://www.ncbi.nlm.nih.gov/pubmed/35528003 http://dx.doi.org/10.3389/fendo.2022.795225 |
_version_ | 1784701103533719552 |
---|---|
author | Olçomendy, Loïc Cassany, Louis Pirog, Antoine Franco, Roberto Puginier, Emilie Jaffredo, Manon Gucik-Derigny, David Ríos, Héctor Ferreira de Loza, Alejandra Gaitan, Julien Raoux, Matthieu Bornat, Yannick Catargi, Bogdan Lang, Jochen Henry, David Renaud, Sylvie Cieslak, Jérôme |
author_facet | Olçomendy, Loïc Cassany, Louis Pirog, Antoine Franco, Roberto Puginier, Emilie Jaffredo, Manon Gucik-Derigny, David Ríos, Héctor Ferreira de Loza, Alejandra Gaitan, Julien Raoux, Matthieu Bornat, Yannick Catargi, Bogdan Lang, Jochen Henry, David Renaud, Sylvie Cieslak, Jérôme |
author_sort | Olçomendy, Loïc |
collection | PubMed |
description | In diabetes mellitus (DM) treatment, Continuous Glucose Monitoring (CGM) linked with insulin delivery becomes the main strategy to improve therapeutic outcomes and quality of patients’ lives. However, Blood Glucose (BG) regulation with CGM is still hampered by limitations of algorithms and glucose sensors. Regarding sensor technology, current electrochemical glucose sensors do not capture the full spectrum of other physiological signals, i.e., lipids, amino acids or hormones, relaying the general body status. Regarding algorithms, variability between and within patients remains the main challenge for optimal BG regulation in closed-loop therapies. This work highlights the simulation benefits to test new sensing and control paradigms which address the previous shortcomings for Type 1 Diabetes (T1D) closed-loop therapies. The UVA/Padova T1DM Simulator is the core element here, which is a computer model of the human metabolic system based on glucose-insulin dynamics in T1D patients. That simulator is approved by the US Food and Drug Administration (FDA) as an alternative for pre-clinical testing of new devices and closed-loop algorithms. To overcome the limitation of standard glucose sensors, the concept of an islet-based biosensor, which could integrate multiple physiological signals through electrical activity measurement, is assessed here in a closed-loop insulin therapy. This investigation has been addressed by an interdisciplinary consortium, from endocrinology to biology, electrophysiology, bio-electronics and control theory. In parallel to the development of an islet-based closed-loop, it also investigates the benefits of robust control theory against the natural variability within a patient population. Using 4 meal scenarios, numerous simulation campaigns were conducted. The analysis of their results then introduces a discussion on the potential benefits of an Artificial Pancreas (AP) system associating the islet-based biosensor with robust algorithms. |
format | Online Article Text |
id | pubmed-9072637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90726372022-05-07 Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes Olçomendy, Loïc Cassany, Louis Pirog, Antoine Franco, Roberto Puginier, Emilie Jaffredo, Manon Gucik-Derigny, David Ríos, Héctor Ferreira de Loza, Alejandra Gaitan, Julien Raoux, Matthieu Bornat, Yannick Catargi, Bogdan Lang, Jochen Henry, David Renaud, Sylvie Cieslak, Jérôme Front Endocrinol (Lausanne) Endocrinology In diabetes mellitus (DM) treatment, Continuous Glucose Monitoring (CGM) linked with insulin delivery becomes the main strategy to improve therapeutic outcomes and quality of patients’ lives. However, Blood Glucose (BG) regulation with CGM is still hampered by limitations of algorithms and glucose sensors. Regarding sensor technology, current electrochemical glucose sensors do not capture the full spectrum of other physiological signals, i.e., lipids, amino acids or hormones, relaying the general body status. Regarding algorithms, variability between and within patients remains the main challenge for optimal BG regulation in closed-loop therapies. This work highlights the simulation benefits to test new sensing and control paradigms which address the previous shortcomings for Type 1 Diabetes (T1D) closed-loop therapies. The UVA/Padova T1DM Simulator is the core element here, which is a computer model of the human metabolic system based on glucose-insulin dynamics in T1D patients. That simulator is approved by the US Food and Drug Administration (FDA) as an alternative for pre-clinical testing of new devices and closed-loop algorithms. To overcome the limitation of standard glucose sensors, the concept of an islet-based biosensor, which could integrate multiple physiological signals through electrical activity measurement, is assessed here in a closed-loop insulin therapy. This investigation has been addressed by an interdisciplinary consortium, from endocrinology to biology, electrophysiology, bio-electronics and control theory. In parallel to the development of an islet-based closed-loop, it also investigates the benefits of robust control theory against the natural variability within a patient population. Using 4 meal scenarios, numerous simulation campaigns were conducted. The analysis of their results then introduces a discussion on the potential benefits of an Artificial Pancreas (AP) system associating the islet-based biosensor with robust algorithms. Frontiers Media S.A. 2022-04-22 /pmc/articles/PMC9072637/ /pubmed/35528003 http://dx.doi.org/10.3389/fendo.2022.795225 Text en Copyright © 2022 Olçomendy, Cassany, Pirog, Franco, Puginier, Jaffredo, Gucik-Derigny, Ríos, Ferreira de Loza, Gaitan, Raoux, Bornat, Catargi, Lang, Henry, Renaud and Cieslak https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Olçomendy, Loïc Cassany, Louis Pirog, Antoine Franco, Roberto Puginier, Emilie Jaffredo, Manon Gucik-Derigny, David Ríos, Héctor Ferreira de Loza, Alejandra Gaitan, Julien Raoux, Matthieu Bornat, Yannick Catargi, Bogdan Lang, Jochen Henry, David Renaud, Sylvie Cieslak, Jérôme Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes |
title | Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes |
title_full | Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes |
title_fullStr | Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes |
title_full_unstemmed | Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes |
title_short | Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes |
title_sort | towards the integration of an islet-based biosensor in closed-loop therapies for patients with type 1 diabetes |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072637/ https://www.ncbi.nlm.nih.gov/pubmed/35528003 http://dx.doi.org/10.3389/fendo.2022.795225 |
work_keys_str_mv | AT olcomendyloic towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT cassanylouis towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT pirogantoine towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT francoroberto towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT puginieremilie towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT jaffredomanon towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT gucikderignydavid towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT rioshector towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT ferreiradelozaalejandra towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT gaitanjulien towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT raouxmatthieu towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT bornatyannick towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT catargibogdan towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT langjochen towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT henrydavid towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT renaudsylvie towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes AT cieslakjerome towardstheintegrationofanisletbasedbiosensorinclosedlooptherapiesforpatientswithtype1diabetes |